2,8-dimethyl-nonane-3,7-dione | 27332-60-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,8-dimethyl-nonane-3,7-dione
• 英文别名: 2,8-Dimethylnonane-3,7-dione
• CAS: 27332-60-1
• 化学式: C₁₁H₂₀O₂
• 分子量: 184.279
• InChiKey: ZDJGGQXAFJLXPZ-UHFFFAOYSA-N

物化性质

• 沸点：
  273.0±23.0 °C(Predicted)
• 密度：
  0.898±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  环辛烷-1,2-二酮 在 platinum(IV) oxide 氢气 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 生成 2,8-dimethyl-nonane-3,7-dione
  参考文献：
  名称：

  Leriverend,P.; Conia,J.-M., Bulletin de la Societe Chimique de France, 1970, p. 1040 - 1050

  摘要：

  DOI：

文献信息

• PRODRUGS OF GUANFACINE
  申请人：Whomsley Rhys

  公开号：US20110065796A1

  公开（公告）日：2011-03-17

  Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration, as well as improving the pharmacokinetics of guanfacine are provided herein.

  本文提供了具有氨基酸或短肽的瓜那非辛前药、含有这种前药的药物组合物以及一种利用瓜那非辛前药在治疗注意力缺陷多动障碍/反抗性违抗障碍（ADHD/ODD）中提供治疗益处的方法。此外，本文还提供了减少或避免与瓜那非辛给药相关的不良胃肠道副作用的方法，以及改善瓜那非辛的药代动力学的方法。
• USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS
  申请人：Franklin Richard

  公开号：US20120202756A1

  公开（公告）日：2012-08-09

  The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.

  本发明涉及各种药物的前药和含有这些前药的制药组合物。还提供了一种方法，用于最小化与未衍生药物相关的局部介导（来自肠腔内）不良胃肠事件，并使用上述前药增加血浆药物水平的持续性。因此，本发明涉及使用各种药物（除阿片类药物外）的前药，以短暂地使它们失活，从而减少通常在给予原始化合物后出现的直接、局部介导的不良胃肠（GI）副作用。此外，这些前药可能提供改善的药代动力学。
• IAP ANTAGONISTS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150322111A1

  公开（公告）日：2015-11-12

  There are disclosed compounds of formula (I) that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

  公开了化合物(I)的配方，该化合物调节凋亡抑制剂(IAPs)的活性，包含该化合物的药物组合物以及利用本发明的化合物治疗增生性疾病和失调凋亡疾病，如癌症的方法。
• Peptide vectors
  申请人：Dong Xin Zheng

  公开号：US20070093645A1

  公开（公告）日：2007-04-26

  The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.
• PEPTIDE-CYTOTOXIC CONJUGATES
  申请人：Dong Zheng Xin

  公开号：US20100113367A1

  公开（公告）日：2010-05-06

  The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.